A Phase 3 interventional study of ETC-1002 and Placebo in Hypercholesterolemia and Atherosclerotic Cardiovascular Diseases, sponsored by Esperion Therapeutics, Inc.. Completed at 104 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-11.
Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one has the largest enrollment, is one of 4 that started in 2016, is one of 7 in phase 3, and was the 7th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
By country, each count listing its studies:
bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,230 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 126 across the 21 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 6 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc., this one has the largest enrollment, is one of 4 that started in 2016, is one of 6 in phase 3, and was the 7th registered.
Esperion Therapeutics, Inc.’s Hypercholesterolemia studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Esperion Therapeutics, Inc.’s 15 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ETC-1002 180 mg/day
Drug: ETC-1002
Placebo control
Drug: Placebo
ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Also known as: bempedoic acid
Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs, defined as adverse events (AEs) that began or worsened in severity after the first dose of double-blind study drug and up to 30 days after receiving the last dose of double-blind study drug, were collected and reported.
Time frame: Up to approximately 52 weeks
Percentage of Participants With Adjudicated Major Adverse Cardiovascular Event
TEAEs, defined as AEs that began or worsened in severity after the first dose of double-blind study drug and up to 30 days after receiving the last dose of double-blind study drug, were collected and reported. Cardiovascular events were considered as adverse events of special interest. Treatment-emergent = TE.
Time frame: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations
TEAEs of special interest (AESIs) were predefined and monitored throughout the study. Creatine kinase elevations were assessed using the following preferred term: Blood creatine phosphokinase increased (system organ class: investigations).
Time frame: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Hepatic Disorders
Treatment-emergent AESIs were predefined and monitored throughout the study. TEAEs potentially related to hepatic events were assessed using the following preferred terms and laboratory abnormalities: aspartate aminotransferase (AST) increased, Alanine aminotransferase (ALT) increased, Hepatic enzyme increased, Blood bilirubin increased, liver function test (LFT) abnormal, LFT increased, hepatic enzyme abnormal, transaminases increased, potential Hy's Law cases (PHLC) \[AST and (\&)/or ALT \>3 x upper limit of normal (ULN) with concurrent total bilirubin \>2 x ULN\], AST and/or ALT \>3 x ULN, and total bilirubin \>2 x ULN (system organ class: investigations). AST and ALT values were repeated and confirmed. "Repeated and confirmed" was defined as a participant having the last on-study LFT \> x ULN, the last on-treatment LFT \> x ULN, or LFT \> x ULN followed by another LFT \> x ULN.
Time frame: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Hypoglycemia
Treatment-emergent AESIs were predefined and monitored throughout the study. Hypoglycemia was assessed using the following preferred terms: hypoglycaemia (system organ class: metabolism and nutrition disorders); blood glucose abnormal and blood glucose decreased (system organ class: investigations). The percentage of unique participants is reported in the "Overall hypoglycemia AESIs" category; a participant could have been represented in more than one of the individual hypoglycemia AESIs.
Time frame: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis
Treatment-emergent AESIs were predefined and monitored throughout the study. Metabolic acidosis was assessed using the preferred term metabolic acidosis (system organ class: metabolism and nutrition disorders).
Time frame: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Muscular Disorder
Treatment-emergent AESIs were predefined and monitored throughout the study. Muscular safety was assessed using the following preferred terms and laboratory abnormalities: myalgia, muscle spasms, pain in extremity, muscular weakness (system organ class: musculoskeletal and connective tissue disorders), and creatine kinase \>5 ULN (repeated and confirmed). The percentage of unique participants is reported in the "Overall muscular disorder AESIs" category; a participant could have been represented in more than one of the individual muscular disorder AESIs.
Time frame: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Neurocognitive Disorder
Treatment-emergent AESIs were predefined and monitored throughout the study. Neurocognitive disorder was assessed using the following preferred terms: memory impairment, amnesia, and cognitive disorder (system organ class: nervous system disorders); confusional state and disorientation (system organ class: psychiatric disorders). The percentage of unique participants is reported in the "Overall neurocognitive disorder AESIs" category; a participant could have been represented in more than one of the individual neurocognitive disorder AESIs.
Time frame: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: New Onset or Worsening Diabetes Mellitus
Treatment-emergent AESIs were predefined and monitored throughout the study. New onset or worsening diabetes was assessed using the following preferred terms: type 2 diabetes mellitus, diabetes mellitus, hyperglycaemia, glucose tolerance impaired, diabetes mellitus inadequate control, and impaired fasting glucose (system organ class: metabolism and nutrition disorders); blood glucose increased, glycosylated haemoglobin increased, blood glucose abnormal, and glucose urine present (system organ class: investigations); and glycosuria (system organ class: renal and urinary disorders). The percentage of unique participants is reported in the "Overall new onset/worsening diabetes mellitus AESIs" category; a participant could have been represented in more than one of the individual new onset/worsening diabetes mellitus AESIs.
Time frame: Up to approximately 52 weeks
Percentage of Participants With the Indicated Event of Special Interest: Renal Disorder
Treatment-emergent AESIs were predefined and monitored throughout the study. TEAEs potentially related to renal events were assessed using the following preferred terms: renal failure, renal impairment, acute kidney injury (system organ class: renal and urinary disorders); blood creatinine increased, glomerular filtration rate decreased, blood urea increased, estimated glomerular filtration rate (eGFR) \<30 milliliter per minute per 1.73 square meter (ml/min/1.73m\^2), and change from baseline in creatinine \>1 mg/dL (system organ class: investigations); and gout (system organ class: metabolism and nutrition disorders). The percentage of unique participants is reported in the "Overall renal disorder AESIs" category; a participant could have been represented in more than one of the individual renal disorder AESIs.
Time frame: Up to approximately 52 weeks
Change From Baseline to Week 52 in Uric Acid (Urate) Level
Blood samples were drawn at defined time points during the course of the study to monitor uric acid (urate) levels.
Time frame: Baseline and Week 52
Change From Baseline to Week 52 in Creatinine Level
Blood samples were drawn at defined time points during the course of the study to monitor creatinine levels.
Time frame: Baseline and Week 52
Change From Baseline to Week 52 in Hemoglobin Level
Blood samples were drawn at defined time points during the course of the study to monitor hemoglobin levels.
Time frame: Baseline and Week 52
Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Least Square mean= LS mean. Percent change was analyzed using the analysis of covariance (ANCOVA) method, which included treatment, randomization stratum as factors, and baseline value as covariate.
Time frame: Baseline; Week 12
Absolute Change From Baseline to Week 12 in LDL-C
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Absolute change from baseline was calculated as: LDL-C value at Week 12 minus Baseline value. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 24 in LDL-C
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.
Time frame: Baseline; Week 24
Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(non-HDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(TC value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apoB. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(apoB value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(hsCRP value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.
Time frame: Baseline; Week 12
Percent Change From Baseline to Week 52 in LDL-C
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.
Time frame: Baseline; Week 52
Percent Change From Baseline to Week 24 in Non-HDL-C
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(non-HDL-C value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
Time frame: Baseline; Week 24
Percent Change From Baseline to Week 52 in Non-HDL-C
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(non-HDL-C value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
Time frame: Baseline; Week 52
Percent Change From Baseline to Week 24 in TC
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(TC value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
Time frame: Baseline; Week 24
Percent Change From Baseline to Week 52 in TC
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(TC value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
Time frame: Baseline; Week 52
Percent Change From Baseline to Week 24 in apoB
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apoB. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(apoB value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed
Time frame: Baseline; Week 24
Percent Change From Baseline to Week 52 in apoB
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apoB. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(apoB value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
Time frame: Baseline; Week 52
Percent Change From Baseline to Week 24 in hsCRP
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(hsCRP value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
Time frame: Baseline; Week 24
Percent Change From Baseline to Week 52 in hsCRP
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(hsCRP value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
Time frame: Baseline; Week 52
Percentage of Participants Achieving LDL-C <70 mg/dL at Week 12, 24, and 52
The percentage of participants who achieved lowering in lipid values of LDL-C below 70 mg/dL have been reported. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Observed data was used for the analysis, no imputation for the missing data was performed.
Time frame: Week 12, Week 24, and Week 52
A total of 2230 participants were randomized 2:1 to either bempedoic acid or placebo. One participant was randomized to bempedoic acid treatment, but never received any dose of investigational medicinal product (IMP) i.e. study drug.
| Milestone | Placebo | Bempedoic Acid |
|---|---|---|
| Started | 742 | 1488 |
| Completed | 706 | 1404 |
| Not completed | 36 | 84 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Adverse event | 12 | 37 |
| Withdrew: Withdrawal by participant | 23 | 40 |
| Withdrew: Sponsor decision | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 |
TEAEs, defined as adverse events (AEs) that began or worsened in severity after the first dose of double-blind study drug and up to 30 days after receiving the last dose of double-blind study drug, were collected and reported.
| percentage of participants | Placebo | Bempedoic Acid |
|---|---|---|
| Any TEAE | 78.7 | 78.5 |
| Any serious TEAE | 14.0 | 14.5 |
| Any fatal TEAE | 0.3 | 0.9 |
| Any TEAE leading to discontinuation of study drug | 7.1 | 10.9 |
TEAEs, defined as AEs that began or worsened in severity after the first dose of double-blind study drug and up to 30 days after receiving the last dose of double-blind study drug, were collected and reported. Cardiovascular events were considered as adverse events of special interest. Treatment-emergent = TE.
| percentage of participants | Placebo | Bempedoic Acid |
|---|---|---|
| Any adjudicated major clinical event | 5.7 | 4.6 |
| Any TE death from cardiovascular causes | 0.1 | 0.4 |
| Any nonfatal myocardial infarction | 1.8 | 1.3 |
| Any nonfatal stroke | 0.3 | 0.3 |
| Any coronary revascularization | 3.2 | 2.6 |
| Any hospitalization for unstable angina | 1.5 | 0.9 |
| TE death from noncardiovascular causes | 0.1 | 0.1 |
| Noncoronary arterial revascularization | 0.8 | 0.3 |
| Hospitalization for heart failure | 0.1 | 0.6 |
TEAEs of special interest (AESIs) were predefined and monitored throughout the study. Creatine kinase elevations were assessed using the following preferred term: Blood creatine phosphokinase increased (system organ class: investigations).
| percentage of participants | Placebo | Bempedoic Acid |
|---|---|---|
| Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations | 1.8 | 2.4 |
Treatment-emergent AESIs were predefined and monitored throughout the study. TEAEs potentially related to hepatic events were assessed using the following preferred terms and laboratory abnormalities: aspartate aminotransferase (AST) increased, Alanine aminotransferase (ALT) increased, Hepatic enzyme increased, Blood bilirubin increased, liver function test (LFT) abnormal, LFT increased, hepatic enzyme abnormal, transaminases increased, potential Hy's Law cases (PHLC) \[AST and (\&)/or ALT \>3 x upper limit of normal (ULN) with concurrent total bilirubin \>2 x ULN\], AST and/or ALT \>3 x ULN, and total bilirubin \>2 x ULN (system organ class: investigations). AST and ALT values were repeated and confirmed. "Repeated and confirmed" was defined as a participant having the last on-study LFT \> x ULN, the last on-treatment LFT \> x ULN, or LFT \> x ULN followed by another LFT \> x ULN.
| percentage of participants | Placebo | Bempedoic Acid |
|---|---|---|
| Overall hepatic disorder AESIs | 1.5 | 2.5 |
| AST increased | 0.4 | 1.5 |
| ALT increased | 0.3 | 0.8 |
| Hepatic enzyme increased | 0.0 | 0.5 |
| Blood bilirubin increased | 0.4 | 0.1 |
| Liver function test abnormal | 0.3 | 0.1 |
| Liver function test increased | 0.1 | 0.2 |
| Hepatic enzyme abnormal | 0.0 | 0.1 |
| Transaminases increased | 0.1 | 0.0 |
| PHLC [AST &/or ALT>3 x ULN, concurrent TB>2 x ULN] | 0.0 | 0.0 |
| AST and/or ALT >3 x ULN | 0.1 | 0.5 |
| Total bilirubin >2 x ULN | 0.0 | 0.0 |
Treatment-emergent AESIs were predefined and monitored throughout the study. Hypoglycemia was assessed using the following preferred terms: hypoglycaemia (system organ class: metabolism and nutrition disorders); blood glucose abnormal and blood glucose decreased (system organ class: investigations). The percentage of unique participants is reported in the "Overall hypoglycemia AESIs" category; a participant could have been represented in more than one of the individual hypoglycemia AESIs.
| percentage of participants | Placebo | Bempedoic Acid |
|---|---|---|
| Overall hypoglycemia AESIs | 3.1 | 2.2 |
| Hypoglycaemia | 3.0 | 2.2 |
| Blood glucose abnormal | 0.1 | 0.1 |
| Blood glucose decreased | 0.0 | 0.1 |
Treatment-emergent AESIs were predefined and monitored throughout the study. Metabolic acidosis was assessed using the preferred term metabolic acidosis (system organ class: metabolism and nutrition disorders).
| percentage of participants | Placebo | Bempedoic Acid |
|---|---|---|
| Percentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis | 0.0 | 0.1 |
Treatment-emergent AESIs were predefined and monitored throughout the study. Muscular safety was assessed using the following preferred terms and laboratory abnormalities: myalgia, muscle spasms, pain in extremity, muscular weakness (system organ class: musculoskeletal and connective tissue disorders), and creatine kinase \>5 ULN (repeated and confirmed). The percentage of unique participants is reported in the "Overall muscular disorder AESIs" category; a participant could have been represented in more than one of the individual muscular disorder AESIs.
| percentage of participants | Placebo | Bempedoic Acid |
|---|---|---|
| Overall muscular disorder AESIs | 10.1 | 13.1 |
| Myalgia | 6.1 | 6.0 |
| Muscle spasms | 2.7 | 4.2 |
| Pain in extremity | 2.2 | 3.4 |
| Muscular weakness | 0.5 | 0.6 |
| Creatine kinase >5 ULN | 0.1 | 0.5 |
Treatment-emergent AESIs were predefined and monitored throughout the study. Neurocognitive disorder was assessed using the following preferred terms: memory impairment, amnesia, and cognitive disorder (system organ class: nervous system disorders); confusional state and disorientation (system organ class: psychiatric disorders). The percentage of unique participants is reported in the "Overall neurocognitive disorder AESIs" category; a participant could have been represented in more than one of the individual neurocognitive disorder AESIs.
| percentage of participants | Placebo | Bempedoic Acid |
|---|---|---|
| Overall neurocognitive disorder AESIs | 0.9 | 0.7 |
| Memory impairment | 0.5 | 0.3 |
| Amnesia | 0.4 | 0.2 |
| Cognitive disorder | 0.0 | 0.1 |
| Confusional state | 0.0 | 0.1 |
| Disorientation | 0.0 | 0.1 |
Treatment-emergent AESIs were predefined and monitored throughout the study. New onset or worsening diabetes was assessed using the following preferred terms: type 2 diabetes mellitus, diabetes mellitus, hyperglycaemia, glucose tolerance impaired, diabetes mellitus inadequate control, and impaired fasting glucose (system organ class: metabolism and nutrition disorders); blood glucose increased, glycosylated haemoglobin increased, blood glucose abnormal, and glucose urine present (system organ class: investigations); and glycosuria (system organ class: renal and urinary disorders). The percentage of unique participants is reported in the "Overall new onset/worsening diabetes mellitus AESIs" category; a participant could have been represented in more than one of the individual new onset/worsening diabetes mellitus AESIs.
| percentage of participants | Placebo | Bempedoic Acid |
|---|---|---|
| Overall new onset/worsening diabetes mellitus AESI | 5.4 | 3.3 |
| Type 2 diabetes mellitus | 0.9 | 1.0 |
| Diabetes mellitus | 0.9 | 0.4 |
| Hyperglycaemia | 0.7 | 0.5 |
| Glucose tolerance impaired | 0.1 | 0.4 |
| Diabetes mellitus inadequate control | 0.4 | 0.1 |
| Impaired fasting glucose | 0.3 | 0.1 |
| Blood glucose increased | 1.2 | 0.7 |
| Glycosylated haemoglobin increased | 0.5 | 0.0 |
| Blood glucose abnormal | 0.1 | 0.1 |
| Glucose urine present | 0.1 | 0.0 |
| Glycosuria | 0.3 | 0.1 |
Treatment-emergent AESIs were predefined and monitored throughout the study. TEAEs potentially related to renal events were assessed using the following preferred terms: renal failure, renal impairment, acute kidney injury (system organ class: renal and urinary disorders); blood creatinine increased, glomerular filtration rate decreased, blood urea increased, estimated glomerular filtration rate (eGFR) \<30 milliliter per minute per 1.73 square meter (ml/min/1.73m\^2), and change from baseline in creatinine \>1 mg/dL (system organ class: investigations); and gout (system organ class: metabolism and nutrition disorders). The percentage of unique participants is reported in the "Overall renal disorder AESIs" category; a participant could have been represented in more than one of the individual renal disorder AESIs.
| percentage of participants | Placebo | Bempedoic Acid |
|---|---|---|
| Renal failure | 0.1 | 0.9 |
| Renal impairment | 0.1 | 0.4 |
| Acute kidney injury | 0.3 | 0.3 |
| Blood creatinine increased | 0.4 | 0.8 |
| Glomerular filtration rate decreased | 0.0 | 0.5 |
| Blood urea increased | 0.1 | 0.1 |
| Gout | 0.3 | 1.2 |
| Change from baseline in creatinine >1 mg/dL | 0.0 | 0.1 |
| eGFR <30 mL/min/1.73 m^2 | 0.4 | 0.9 |
Blood samples were drawn at defined time points during the course of the study to monitor uric acid (urate) levels.
| milligrams per deciliter (mg/dL) | Placebo | Bempedoic Acid |
|---|---|---|
| Baseline | 5.96 ± 1.35 | 6.06 ± 1.37 |
| Change from Baseline at Week 52 | -0.06 ± 0.87 | 0.73 ± 1.11 |
Blood samples were drawn at defined time points during the course of the study to monitor creatinine levels.
| mg/dL | Placebo | Bempedoic Acid |
|---|---|---|
| Baseline | 0.96 ± 0.22 | 0.97 ± 0.22 |
| Change from Baseline at Week 52 | -0.02 ± 0.12 | 0.02 ± 0.13 |
Blood samples were drawn at defined time points during the course of the study to monitor hemoglobin levels.
| grams per deciliter (g/dL) | Placebo | Bempedoic Acid |
|---|---|---|
| Baseline | 14.07 ± 1.26 | 14.22 ± 1.26 |
| Change from Baseline at Week 52 | -0.23 ± 0.85 | -0.58 ± 0.88 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Least Square mean= LS mean. Percent change was analyzed using the analysis of covariance (ANCOVA) method, which included treatment, randomization stratum as factors, and baseline value as covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) | 1.6 ± 0.86 | -16.5 ± 0.52 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Absolute change from baseline was calculated as: LDL-C value at Week 12 minus Baseline value. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen.
| mg/dL | Placebo | Bempedoic Acid |
|---|---|---|
| Absolute Change From Baseline to Week 12 in LDL-C | 0.43 ± 27.04 | -19.23 ± 24.01 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 24 in LDL-C | 1.2 ± 0.88 | -14.9 ± 0.60 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(non-HDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | 1.5 ± 0.76 | -11.9 ± 0.48 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(TC value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Total Cholesterol (TC) | 0.8 ± 0.57 | -10.3 ± 0.37 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apoB. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(apoB value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB) | 3.3 ± 0.70 | -8.6 ± 0.47 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(hsCRP value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP) | 2.6 ± 91.9 | -22.4 ± 72.5 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 52 in LDL-C | 1.0 ± 0.92 | -12.6 ± 0.66 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(non-HDL-C value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 24 in Non-HDL-C | 1.61 ± 20.91 | -11.69 ± 19.80 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(non-HDL-C value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 52 in Non-HDL-C | 0.65 ± 21.438 | -10.07 ± 22.097 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(TC value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 24 in TC | 1.15 ± 15.349 | -9.86 ± 15.358 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(TC value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 52 in TC | 0.38 ± 16.180 | -8.92 ± 16.945 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apoB. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(apoB value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 24 in apoB | 4.8 ± 20.41 | -7.1 ± 20.01 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apoB. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(apoB value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 52 in apoB | 3.4 ± 20.24 | -6.0 ± 22.54 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(hsCRP value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 24 in hsCRP | 2.727 (-33.028 to 59.016) | -16.382 (-51.329 to 34.436) |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(hsCRP value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.
| percent change | Placebo | Bempedoic Acid |
|---|---|---|
| Percent Change From Baseline to Week 52 in hsCRP | 1.818 (-36.508 to 60.952) | -14.445 (-50.000 to 43.889) |
The percentage of participants who achieved lowering in lipid values of LDL-C below 70 mg/dL have been reported. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Observed data was used for the analysis, no imputation for the missing data was performed.
| Percentage of participants | Placebo | Bempedoic Acid |
|---|---|---|
| Week 12 | 9.0 | 32.4 |
| Week 24 | 10.2 | 32.0 |
| Week 52 | 9.5 | 28.2 |
Collected over Up to approximately 52 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bempedoic Acid | 13/1,487 (0.9%) | 216/1,487 (14.5%) | 792/1,487 (53.3%) |
| Placebo | 2/742 (0.3%) | 104/742 (14%) | 381/742 (51.3%) |
| Event | Bempedoic Acid | Placebo |
|---|---|---|
| Angina unstableCardiac disorders | 18/1487 | 12/742 |
| Angina pectorisCardiac disorders | 11/1487 | 6/742 |
| Coronary artery diseaseCardiac disorders | 9/1487 | 6/742 |
| Acute myocardial infarctionCardiac disorders | 11/1487 | 5/742 |
| Myocardial infarctionCardiac disorders | 8/1487 | 5/742 |
| Non-cardiac chest painGeneral disorders | 7/1487 | 4/742 |
| Atrial fibrillationCardiac disorders | 7/1487 | 1/742 |
| Cardiac failureCardiac disorders | 5/1487 | 3/742 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/1487 | 3/742 |
| SyncopeNervous system disorders | 3/1487 | 3/742 |
| Event | Bempedoic Acid | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 146/1487 | 87/742 |
| Urinary tract infectionInfections and infestations | 70/1487 | 47/742 |
| MyalgiaMusculoskeletal and connective tissue disorders | 89/1487 | 45/742 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 64/1487 | 44/742 |
| Upper respiratory tract infectionInfections and infestations | 72/1487 | 31/742 |
| DizzinessNervous system disorders | 65/1487 | 31/742 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 62/1487 | 20/742 |
| DiarrhoeaGastrointestinal disorders | 60/1487 | 30/742 |
| Back painMusculoskeletal and connective tissue disorders | 55/1487 | 18/742 |
| HypertensionVascular disorders | 42/1487 | 26/742 |
| Age, Continuous(years) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Mean | 66.8 ± 8.64 | 65.8 ± 9.11 | 66.1 ± 8.96 |
| Sex: Female, Male(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Female | 213 | 389 | 602 |
| Male | 529 | 1099 | 1628 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 24 | 35 |
| Not Hispanic or Latino | 731 | 1464 | 2195 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 8 | 14 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| Black or African American | 15 | 42 | 57 |
| White | 716 | 1423 | 2139 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 2 | 4 | 6 |
| Cardiovascular history: atherosclerotic cardiovascular disease (ASCVD)(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Yes | 727 | 1449 | 2176 |
| No | 15 | 39 | 54 |
| Cardiovascular history: heterozygous familial hypercholesterolemia (HeFH)(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Yes | 23 | 56 | 79 |
| No | 719 | 1432 | 2151 |
| History of diabetes(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Yes | 212 | 425 | 637 |
| No | 530 | 1063 | 1593 |
| History of hypertension(Participants) | Placebo | Bempedoic Acid | Total |
|---|---|---|---|
| Yes | 594 | 1174 | 1768 |
| No | 148 | 314 | 462 |
13 further baseline measures are reported on the registry.
Showing the first 100 of 104 sites across 6 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2016 to primary completion in Feb 2018, 25 months.
Results were first posted in Apr 2020, 2 years 1 month after primary completion. A results delay was requested in Jul 2018.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 25 months is above that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid